ACXP (acurxpharma.com) Net Profit

Official company branding of Acurx Pharmaceuticals (ACXP)

The scientific authority of Acurx Pharmaceuticals (ACXP) management is confirmed by the trust of specialized funds. The company's financial performance trend visualizes the results of their activities, where -0.01 shows the value of this parameter. The business creates unique antibiotics against C. diff that preserve gut microbiota. Meanwhile, the lack of operating cash flow makes the issuer's stability dependent on external investments and clinical trial stages.

ACXP (Acurx) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for acurxpharma.com (ACXP)

- price and consensus price forecast:
Stock Quotes Acurx Pharmaceuticals, Inc.|ACXP - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Acurx Pharmaceuticals, Inc.|ACXP - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Acurx Pharmaceuticals|ACXP - Company Book Value|Market Cap to Net Assets Ratio acurxpharma.com|ACXP - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Acurx Pharmaceuticals|ACXP - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Acurx Pharmaceuticals, Inc.|ACXP - Company Debts|Debt to Net Assets Ratio Acurx Pharmaceuticals, Inc.|ACXP - Company Long-Term Debt|Short-Term Debt Acurx Pharmaceuticals|Quick Liquidity acurxpharma.com
- net income and valuation multiples indicators:
ACXP - Net Profit
Basic company analysis:Acurx (ACXP)
Mass-produced product of Acurx Pharmaceuticals Inc.

This indicator captures the actual financial result net of all operating and debt obligations, allowing for a real-time assessment of the business's solvency. By analyzing the profit trajectory of Acurx Pharmaceuticals (ACXP), an investor can gauge the monetization efficiency of its selective antibiotic developments, which is critical for evaluating the sustainability of a biopharmaceutical startup during periods of expensive borrowed capital.

Main competitors

Net Income Armata